These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32132149)

  • 1. Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits.
    Richardson DR; Crossnohere NL; Seo J; Estey E; O'Donoghue B; Smith BD; Bridges JFP
    Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):942-948. PubMed ID: 32132149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.
    Seo J; Smith BD; Estey E; Voyard E; O' Donoghue B; Bridges JFP
    Curr Med Res Opin; 2018 Dec; 34(12):2031-2039. PubMed ID: 29565196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
    Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
    Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' Preferences for Artificial Intelligence Applications Versus Clinicians in Disease Diagnosis During the SARS-CoV-2 Pandemic in China: Discrete Choice Experiment.
    Liu T; Tsang W; Huang F; Lau OY; Chen Y; Sheng J; Guo Y; Akinwunmi B; Zhang CJ; Ming WK
    J Med Internet Res; 2021 Feb; 23(2):e22841. PubMed ID: 33493130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alignment of preferences in the treatment of multiple myeloma - a discrete choice experiment of patient, carer, physician, and nurse preferences.
    Fifer SJ; Ho KA; Lybrand S; Axford LJ; Roach S
    BMC Cancer; 2020 Jun; 20(1):546. PubMed ID: 32527324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous Patient Preferences for Modern Antiretroviral Therapy: Results of a Discrete Choice Experiment.
    Ostermann J; Mühlbacher A; Brown DS; Regier DA; Hobbie A; Weinhold A; Alshareef N; Derrick C; Thielman NM
    Value Health; 2020 Jul; 23(7):851-861. PubMed ID: 32762986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.
    Kreissl S; Goergen H; Müller H; Meissner J; Mehnert A; Bürkle C; Fuchs M; Engert A; Behringer K; Borchmann P
    Leuk Lymphoma; 2019 Jun; 60(6):1389-1398. PubMed ID: 30507313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment.
    Ravelo A; Myers K; Brumble R; Bussberg C; Koffman B; Manzoor BS; Biondo JML; Mansfield C
    Future Oncol; 2024; 20(28):2059-2070. PubMed ID: 38861284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
    Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
    Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
    Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Childhood Acute Myeloid Leukemia in Bulgaria.
    Burnusuzov HA; Yordanova MN; Avramova BE; Yurukova NN; Bachvarov KN; Muchinova AB; Vlahova IH; Stoyanova AA; Mumdzhiev IN; Ivanova LR; Spasov NY; Peteva ET; Belcheva MI; Hristozova H; Spasova MI; Kaleva VI; Bobev D; Konstantinov DN
    Folia Med (Plovdiv); 2018 Jun; 60(2):234-240. PubMed ID: 30355812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom.
    Castejón N; Cappelleri JC; Cuervo J; Lang K; Mehta P; Mokgokong R; Mamolo C
    Health Qual Life Outcomes; 2018 Apr; 16(1):66. PubMed ID: 29669568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliciting Preferences for Health Insurance in Iran Using Discrete Choice Experiment Analysis.
    Kazemi Karyani A; Akbari Sari A; Woldemichael A
    Int J Health Policy Manag; 2019 Aug; 8(8):488-497. PubMed ID: 31441289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: Discrete choice experiment eliciting preferences in real-world study "VOTE".
    Rosenow F; Winter Y; Leunikava I; Brunnert M; Joeres L; Sutphin J; Boeri M; Smith J; Villani F; Brandt C
    Epilepsia; 2022 Feb; 63(2):451-462. PubMed ID: 34921391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center.
    Jaime-Pérez JC; Padilla-Medina JR; Fernández LT; Herrera-Garza JL; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Gómez-Almaguer D
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):286-292. PubMed ID: 29478946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferences for risks and benefits of treatment outcomes for chronic low back pain: Choice-based conjoint measure development and discrete choice experiment.
    Wilson L; Denham A; Ionova Y; O'Neill C; Greco CM; Hassett AL; Hanmer J; Shaikh S; Wolf M; Berven S; Williams D; Ma Y; Lotz J; Zheng P
    PM R; 2024 Aug; 16(8):836-847. PubMed ID: 38040670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.